REFERENCES

1. Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C.,George, J., et al. (2012). BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian ovarian cancer study group. Journal of Clinical Oncology, 30(21), 2654–2663.
2. Candido-dos-Reis, F. J., Song, H., Goode, E. L., Cunningham, J. M., Fridley, B. L., Larson, M. C., et al., Australian Ovarian Cancer Study, G. (2015). Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. Clinical Cancer Research, 21(3), 652–657.
3. Domchek, S. M., Jhaveri, K., Patil, S., Stopfer, J. E., Hudis, C., Powers, J., et al. (2013). Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. Cancer, 119(7), 1344–1348.
4. Easton, D. F., Pharoah, P. D., Antoniou, A. C., Tischkowitz, M., Tavtigian, S. V., Nathanson, K. L., & Foulkes, W. D. (2015). Gene-panel sequencing and the prediction of breast-cancer risk. The New England Journal of Medicine, 372(23), 2243–2257.
5. Gangi, A., Cass, I., Paik, D., Barmparas, G., Karlan, B., Dang, C., & Amersi, F. F. (2014). Breast cancer following ovarian cancer in BRCA mutation carriers. JAMA Surgery, 149(12), 1306–1313.
6. Hartmann, L. C., & Lindor, N. M. (2015). The role of risk-reducing surgery in hereditary breast and ovarian cancer. New England Journal of Medicine, 374(5), 454–468.
7. Konecny, G. E., & Kristeleit, R. S. (2016). PARP inhibitors for BRCA1/ 2-mutated and sporadic ovarian cancer: Current practice and future directions. British Journal of Cancer, 115(10), 1157–1173.
8. Kriege, M., Brekelmans, C. T., Boetes, C., Besnard, P. E., Zonderland, H. M., Obdeijn, I. M., & Magnetic Resonance Imaging Screening Study, G. (2004). Efficacy of MRI and mammography for breast cancer screening in women with a familial or genetic predisposition. The New England Journal of Medicine, 351(5), 427–437.
9. Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., & Embrace. (2013). Cancer risks for BRCA1 and BRCA2 mutation carriers: Results from prospective analysis of EMBRACE. Journal of the National Cancer Institute, 105(11), 812–822.